» Articles » PMID: 24513568

The Use of Chimeric Virus-like Particles Harbouring a Segment of Hantavirus Gc Glycoprotein to Generate a Broadly-reactive Hantavirus-specific Monoclonal Antibody

Overview
Journal Viruses
Publisher MDPI
Specialty Microbiology
Date 2014 Feb 12
PMID 24513568
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Monoclonal antibodies (MAbs) against viral glycoproteins have important diagnostic and therapeutic applications. In most cases, the MAbs specific to viral glycoproteins are raised against intact virus particles. The biosynthesis of viral glycoproteins in heterologous expression systems such as bacteria, yeast, insect or mammalian cells is often problematic due to their low expression level, improper folding and limited stability. To generate MAbs against hantavirus glycoprotein Gc, we have used initially a recombinant yeast-expressed full-length Puumala virus (PUUV) Gc protein. However, this approach was unsuccessful. As an alternative recombinant antigen, chimeric virus-like particles (VLPs) harboring a segment of PUUV Gc glycoprotein were generated in yeast Saccharomyces cerevisiae. A 99 amino acid (aa)-long segment of Gc protein was inserted into the major capsid protein VP1 of hamster polyomavirus at previously defined positions: either site #1 (aa 80-89) or site #4 (aa 280-289). The chimeric proteins were found to self-assemble to VLPs as evidenced by electron microscopy. Chimeric VLPs induced an efficient insert-specific antibody response in immunized mice. Monoclonal antibody (clone #10B8) of IgG isotype specific to hantavirus Gc glycoprotein was generated. It recognized recombinant full-length PUUV Gc glycoprotein both in ELISA and Western blot assay and reacted specifically with hantavirus-infected cells in immunofluorescence assay. Epitope mapping studies revealed the N-terminally located epitope highly conserved among different hantavirus strains. In conclusion, our approach to use chimeric VLPs was proven useful for the generation of virus-reactive MAb against hantavirus Gc glycoprotein. The generated broadly-reactive MAb #10B8 might be useful for various diagnostic applications.

Citing Articles

Achievement and Challenges in Orthohantavirus Vaccines.

Chai S, Wang L, Du H, Jiang H Vaccines (Basel). 2025; 13(2).

PMID: 40006744 PMC: 11861054. DOI: 10.3390/vaccines13020198.


Immunization with GP1 but Not Core-like Particles Displaying Isolated Receptor-Binding Epitopes Elicits Virus-Neutralizing Antibodies against Junín Virus.

Roman-Sosa G, Leske A, Ficht X, Dau T, Holzerland J, Hoenen T Vaccines (Basel). 2022; 10(2).

PMID: 35214632 PMC: 8874384. DOI: 10.3390/vaccines10020173.


Hamster Polyomavirus Research: Past, Present, and Future.

Jandrig B, Krause H, Zimmermann W, Vasiliunaite E, Gedvilaite A, Ulrich R Viruses. 2021; 13(5).

PMID: 34068409 PMC: 8153644. DOI: 10.3390/v13050907.


Vaccination with Prion Peptide-Displaying Polyomavirus-Like Particles Prolongs Incubation Time in Scrapie-Infected Mice.

Eiden M, Gedvilaite A, Leidel F, Ulrich R, Groschup M Viruses. 2021; 13(5).

PMID: 33946367 PMC: 8147134. DOI: 10.3390/v13050811.


Isolation and characterization of new Puumala orthohantavirus strains from Germany.

Binder F, Reiche S, Roman-Sosa G, Saathoff M, Ryll R, Trimpert J Virus Genes. 2020; 56(4):448-460.

PMID: 32328924 PMC: 7329759. DOI: 10.1007/s11262-020-01755-3.


References
1.
Brocato R, Josleyn M, Wahl-Jensen V, Schmaljohn C, Hooper J . Construction and nonclinical testing of a Puumala virus synthetic M gene-based DNA vaccine. Clin Vaccine Immunol. 2012; 20(2):218-26. PMC: 3571280. DOI: 10.1128/CVI.00546-12. View

2.
Sakamoto S, Ide T, Tokiyoshi S, NAKAO J, Hamada F, Yamamoto M . Studies on the structures and antigenic properties of rabies virus glycoprotein analogues produced in yeast cells. Vaccine. 1999; 17(3):205-18. DOI: 10.1016/s0264-410x(98)00196-0. View

3.
Schmaljohn C . Vaccines for hantaviruses: progress and issues. Expert Rev Vaccines. 2012; 11(5):511-3. DOI: 10.1586/erv.12.15. View

4.
Guttieri M, Bookwalter C, Schmaljohn C . Expression of a human, neutralizing monoclonal antibody specific to puumala virus G2-protein in stably-transformed insect cells. J Immunol Methods. 2000; 246(1-2):97-108. DOI: 10.1016/s0022-1759(00)00299-4. View

5.
Hepojoki J, Strandin T, Lankinen H, Vaheri A . Hantavirus structure--molecular interactions behind the scene. J Gen Virol. 2012; 93(Pt 8):1631-1644. DOI: 10.1099/vir.0.042218-0. View